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Dosimetry-based treatment for Graves’ disease
Steve L. Hyera, Brenda Prattb, Matthew Grayb, Sarah Chittendenb, Yong Duc,
Clive L. Harmerd and Glenn D. Fluxb
Objective The aim of this retrospective study was to
assess the long-term outcome of a personalized dosimetry
approach in Graves’ disease aiming to render patients
euthyroid from a planned thyroid absorbed dose of 60 Gy.
Patients and methods A total of 284 patients with Graves’
disease were followed prospectively following
administration of radioiodine calculated to deliver an
absorbed dose of 60 Gy. Patients with cardiac disease were
excluded. Outcomes were analysed at yearly intervals for up
to 10 years with a median follow-up of 37.5 months.
Results A single radioiodine administration was sufficient
to render a patient either euthyroid or hypothyroid in 175
(62%) patients, the remainder requiring further radioiodine.
The median radioactivity required to deliver 60 Gy was
77MBq. Less than 2% patients required 400–600MBq, the
standard activity administered in many centres. In the cohort
receiving a single administration, 38, 32 and 26% were
euthyroid on no specific thyroid medication at 3, 5 and
10 years, respectively. Larger thyroid volumes were
associated with the need for further therapy.
The presence of nodules on ultrasonography did not
adversely affect treatment outcome.
Conclusion A personalized dosimetric approach delayed
the long-term onset of hypothyroidism in 26% of patients.
This was achieved using much lower administered activities
than currently recommended. Future studies will aim to
identify those patients who would benefit most from this
approach. Nucl Med Commun 00:000–000 Copyright ©
2018 The Author(s). Published by Wolters Kluwer Health,
Inc.
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Introduction
The optimal radioiodine treatment strategy for Graves’
disease is controversial as reflected in the differing gui-
dance offered by international guidelines. The American
Thyroid Association aims to render patients hypothyroid
by administering 370–555MBq (10–15 mCi) or 5.5MBq
(150 mCi) per gram of thyroid tissue [1]. The Royal
College of Physicians (UK) recommends a fixed activity
of 400–600MBq for rapid elimination of hyperthyroidism
accepting that a significant proportion of patients will
require life-long L-thyroxine with this approach [2]. In
contrast, the European Association of Nuclear Medicine
recommends administration of an activity of radioiodine
calculated to give an absorbed dose of 150 Gy to the
thyroid where the aim is to restore euthyroidism [3].
A fixed activity approach has the advantages of cost-
effectiveness, efficiency and early eradication of hyper-
thyroidism thus avoiding its adverse consequences [4–6].
In contrast, an individualized approach on the basis of
dosimetry aims to administer the minimum activity of
radioiodine necessary to render a patient euthyroid for
the maximum length of time in accordance with the
ionizing radiation regulations, which are guided by the
ALARA (as low as reasonably achievable) principle in
radiation protection, that is to keep radiation doses ‘as low
as reasonably achievable’ and stipulate that exposures of
target volumes must be individually planned [7]. The
disadvantage of remaining on antithyroid medication for
longer with this approach is offset by the delayed need for
L-thyroxine replacement since ∼ 40% of patients on long-
term L-thyroxine are either over-treated or under-treated,
and hence at risk of associated morbidities [8].
Following an initial study that demonstrated that an
absorbed dose of more than 40 Gy iodine-131 (131I) was
needed to achieve short-term control of hyperthyroidism
in Graves’ disease [9], the long-term prospective study
presented here was performed to assess the feasibility
and effectiveness of an activity administration calculated
to deliver 60 Gy to the thyroid. Treatment outcomes, in
terms of hyperthyroidism, hypothyroidism and euthyr-
oidism were investigated with up to 10 years follow-up.
In addition, clinical and 131I kinetic parameters that might
predict treatment outcome were examined.
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Patients and methods
Patients
Over a 10-year period (1999–2009), 284 patients [216
female, 67 male: mean age of 46.2 years (range:
18.1–81.6 years)] referred to the Thyroid Unit at the
Royal Marsden Hospital for 131I treatment of Graves’
disease participated in this study, which was approved by
the Royal Marsden Hospital Research Ethics Committee.
Inclusion criteria stipulated clinical and biochemically
proven Graves’ disease and no previous radioiodine
treatment. All patients provided written informed con-
sent after receiving detailed information about radio-
iodine treatment including printed radiation protection
instructions. Patients with multinodular goitre, autono-
mous thyroid nodules or cardiac complications (heart
failure or atrial fibrillation) were excluded from the study.
Patients who were unable or unwilling to come up for the
additional six visits required for dosimetry underwent
standard treatment with a fixed radioactive iodine dose of
75MBq.
The diagnosis of Graves’ disease was made according to
standard criteria: typical clinical findings and the pre-
sence of thyroid-stimulating hormone (TSH) receptor
autoantibodies. Those with a diffuse and homogenous
pattern on technetium-99m-scintigraphy were classified
as typical Graves’ disease (227 patients). The remaining
57 patients with nonuniform uptake on scintigraphy or
nodular appearance on thyroid ultrasound scanning were
classified as Graves’ disease in a nodular thyroid. Thyroid
volume was determined immediately before a tracer
administration of radioiodine. Radioiodine kinetics was
determined following tracer and therapy administrations
of Na131I.
The study schedule is shown in Table 1. Patients were
advised to follow a low-iodine diet and to stop antithyroid
medication commencing 3 days before radioiodine
administration and continuing for 9 and 6 days for tracer
and therapy, respectively. Tracer and therapy adminis-
trations were 14 days apart. This schedule ensured that
patients were euthyroid at the time of 131I treatment,
thus minimizing the risk of thyroid storm. In addition, it
allowed tracer and therapy administrations to be given
under the same physiological conditions. Those patients
with clinical evidence of thyroid eye disease received
0.5 mg/kg oral prednisolone with the radioiodine at
therapy and with the tracer administration to prevent
ophthalmopathy worsening.
Measurements
Thyroid volume
Thyroid volume was assessed by ultrasound performed
immediately before tracer administration. Thyroid
volume was calculated from the formula: Vlobe= length
(cm)×width (cm)× depth (cm)×m (where m= 0.479)
taking the maximal linear dimensions of each lobe on a
frozen B-scan image [10]. Texture was graded as homo-
geneous, heterogeneous or nodular.
Radioiodine kinetics
Following oral administration of a 0.37MBq Na131I tracer
administration, radioiodine uptake in the thyroid was
measured using a sodium iodide detector with diverging
collimator. Thyroid uptake was determined by compar-
ison of the count rates from the patient’s thyroid and a
known activity of 131I in a standard neck phantom.
Background counts were measured with a lead shield
positioned between the front of the collimator and the
patient’s neck or phantom. Percentage thyroid uptake
was determined at 1, 2 and 6 days following the tracer
administration:
U ¼ CRPAS100
CRSAP ;
where U (%) is the percentage thyroid uptake, CRP is the
patient count rate (cpm), AS is the activity of the standard
(MBq), CRS is the count rate of the standard (cpm) and
AP is the activity in the patient (MBq).
For each patient, the maximum recorded thyroid uptake
(U) and the uptake at 6 days were used to determine the
effective half-life (days). The effective half-life was set to
8 days in cases where it was calculated to be greater than
this value.
Dosimetry
The activity (A) of 131I needed to deliver 60 Gy to the
thyroid was calculated from the following equation on the
basis of the Medical Internal Radiation Dose schema:
A¼ 60M
0:037UT ;
where 60 is the target thyroid absorbed dose (Gy), M is
the mass of the thyroid (g), U is the maximum uptake in
the thyroid (%) and T is the effective half-life in the
thyroid (days).
Table 1 Summary of study schedule
Day −3 Stop antithyroid medication
Start low-iodine diet
Day 0 Ultrasound scan of thyroid
Administration of radioiodine tracer
Day 1 Thyroid uptake measured
Day 2 Thyroid uptake measured
Day 6 Thyroid uptake measured
Resume antithyroid medication
Resume normal diet
Day 11 Stop antithyroid medication
Start low-iodine diet
Day 14 Administration of radioiodine treatment
Day 15 Thyroid uptake measured
Scintillation imaging
Day 17 Resume antithyroid medication
Resume normal diet
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Radioiodine therapy was administered 1–2 weeks after
the tracer study. At 24 h after therapy administration the
thyroid uptake was measured using the same system and
setup as for the tracer study. Owing to the high 131I
activity present it was necessary to attach a secondary
collimator to the diverging collimator to reduce the sen-
sitivity of the system and thus avoid problems resulting
from dead-time. The absorbed dose to the thyroid was
then calculated using the thyroid volume and effective
half-life calculated in the tracer study.
A gamma camera image was also taken at this time to
assess heterogeneity of uptake.
Following radioiodine therapy, antithyroid medications
were restarted and continued until patients were clini-
cally and biochemically euthyroid. All patients received
radiation protection advice regarding contact with chil-
dren and time off work in line with standard guidelines.
Patients were advised to avoid close contact with young
children (< 3 years) for 7 days and there was no restriction
on work with adults unless contact with pregnant women
was possible. Patients attended follow-up at regular visits
for a minimum of 12 months up to 10 years with a median
follow-up of 37.5 months. At each visit thyroid status was
evaluated clinically and biochemically and patients were
classified as hypothyroid requiring L-thyroxine (elevated
TSH with or without low FT4), hyperthyroid requiring
antithyroid treatment (elevated FT4 or FT3 and low
TSH) or euthyroid on no specific thyroid medication
(normal FT4, FT3 and measurable TSH). The require-
ment for a further administration of 131I was based on
clinical assessment. A second administration of 131I was
considered an outcome endpoint and any such patients
left the study to be followed in the standard endocrine
clinic.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
and Bell Laboratories statistical computing package
(Graphpad software; San Diego, California, USA), ‘R’.
Descriptive statistics are provided as mean ± SD for nor-
mally distributed data or as median with 95% confidence
intervals (CIs) and range for non-normally distributed
data. Thyroid status was analysed at 6 months, 1, 3, 5 and
10 years. For the purpose of analysis it was assumed
that patients who were hypothyroid on L-thyroxine
replacement at discharge remained in the same state.
For multivariate analysis to compare baseline variables
(thyroid volume, age, 131I uptake, effective half-life) and
thyroid status, we used logistic regression analysis. The
coefficients of the independent variables in the regres-
sion were transformed to give the odds of a particular
treatment outcome. The odds ratios (ORs) are expressed
with 95% CIs. The regression was repeated at 3, 5 and
10 years with P value less than 0.05 taken as indicating
statistical significance in all tests. All P values presented
are two tailed.
Results
Baseline measurements
Baseline characteristics are shown in Tables 2 and 3. In
comparison with patients with typical Graves’ disease,
those with Graves’ in a nodular goitre were more likely to
be male, older and to require more activity to achieve the
target 60 Gy absorbed dose. The maximum uptake of 131I
after tracer and therapy administrations was reduced in
nodular glands although the 131I effective half-life was
slightly but not significantly longer. Only five patients
required 400MBq or more to deliver a target absorbed
dose of 60 Gy. The maximum thyroidal 131I uptake was
very similar for the tracer and therapy (Table 3). The
median thyroid volume was greater in the group with
nodules. Five patients requiring over 400MBq had sig-
nificantly larger thyroid volumes (mean: 56.4 ml; range:
37.9–96.8 ml; P< 0.05). Median effective half-life in
Graves’ and Graves’ with nodules was not found to be
statistically significant. Analysis of the whole patient
cohort gave a median absorbed thyroid dose of 55.8 Gy
(55.03–58.03).
Treatment outcomes
Clinical outcomes for patients with typical Graves’ disease
(n=227) and Graves’ in a nodular thyroid (n=57) are
shown in Fig. 1. At 18 months, 44.2% of all study patients
were euthyroid on no specific therapy, 9.0% were on
replacement L-thyroxine, 11.6% were still taking antithyroid
medication and 35.2% had required a second administration
of 131I (fixed dose of 75MBq) because of persistent
hyperthyroidism requiring antithyroid medication.
The proportion of patients requiring further radioiodine
increased to 43.8% by 3 years but thereafter changed
little (47.0% at 5 years, 48.6% at 10 years). No serious
adverse effects of radioiodine (post-therapy flare of
hyperthyroidism or significant exacerbation of thyroid
eye disease) were observed. At 3, 5 and 10 years after
administration, 41.4, 37.7 and 30.0%, respectively of
patients were euthyroid on no thyroid medication. The
proportion of patients becoming hypothyroid increased
from 12.9% at 3 years to 17.0% at 5 years and 21.4% at
10 years. After 3 years, a small percentage of patients
were still on antithyroid medication usually because
further 131I therapy was contraindicated. By 5 years no
patients remained on antithyroid drugs.
Table 2 Baseline characteristics with univariate analysis
Patients (n) Male : female Age [median (range)] (years)
Graves (227) 60 : 167 44 (18–75)
Graves + nodules (57) 7 : 50 53 (21–82)
All (284) 67 : 217 18–82
P value 0.0239b 0.0001a
aMann–Whitney U-nonparametric testing (P<0.05 indicates significance).
bFishers exact test.
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In comparison with patients with typical Graves’ disease,
those with Graves’ in a nodular thyroid became non-
hyperthyroid sooner and none required antithyroid
medication by 3 years (Fig. 1). At 10 years, a slightly
greater proportion were euthyroid (33.3 vs. 29.2%) or
hypothyroid (22.9 vs. 21.0%) and fewer had required a
second administration of 131I (43.8 vs. 49.7%).
Factors affecting treatment outcomes
Thyroid volume
From multivariate analysis, increasing thyroid volume was
found to be highly significant in the likelihood of a patient
responding to a single administration of 131I. The ORs (95%
CIs) for achieving a nonhyperthyroid state (euthyroidism or
hypothyroidism on L-thyroxine) are shown in Table 4. At
3 years, ORwas 1.044 (1.014–1.077, P=0.005), at 5 years the
OR had decreased to 1.04 (1.011–1.074, P=0.008) and at
10 years to 1.032 (1.004–1.063, P=0.029). Thyroid volume
did not correlate with effective 131I half-life or maximum
percentage 131I uptake.
Age at treatment
Increasing age at the point of treatment was significantly
associated with the likelihood of a patient successfully
responding to a single administration (Fig. 2). The cor-
responding ORs at 3, 5 and 10 years were very similar at
0.976 (0.955–0.997), 0.97 and 0.969.
Effective iodine-131 half-life and maximum iodine-131
uptake
Neither effective half-life nor maximum 131I uptake were
significantly associated with the need for further 131I
treatment.
Duration of antithyroid treatment
We found no significant association between length of
antithyroid treatment before 131I treatment and treat-
ment outcomes.
Discussion
The results of this study indicated that a targeted 60 Gy
absorbed dose to the thyroid can delay the onset of
hypothyroidism in about a quarter of patients with
Graves’ disease. Using the protocol adopted in this study,
62% of patients were treated once with a mean 131I
activity of 106MBq. The remainder required a second
131I administration usually within 2 years. In patients
receiving a single administration, euthyroidism persisted
Table 3 Metrics for calculating a fixed target absorbed dose of 60 Gy to the thyroid
Na131I activity [median
(range)] (MBq)
Thyroid volume [median
(range)] (ml)
Effective half-life [median
(range)] (days)
Diagnostic uptake [mean
(range)] (%)
Therapeutic uptake [mean
(range)] (%)
Graves 76 (17.4–400) 16.9 (3.1–52.4) 5.18 (1.15–8) 60.27 (14.8–95.9) 57.1 (18.5–96)
Graves +nodules 99 (33–1377) 20.2 (4.5–96.8) 5.45 (1.35–8) 53.6 (23.2–85.4) 50.5 (19.9–82.1)
All 17.4–1377 3.1–96.8 1.15–8 14.8–95.9 18.5–96
P value 0.0309a 0.0381b 0.3589a 0.0019b 0.0020b
aMann–Whitney U-nonparametric testing (P<0.05 indicates significance).
bUnpaired two-tailed t-test (P<0.05 indicates significance).
Fig. 1
Treatment outcomes for patients with Graves’ disease (n=227) (solid lines) and for Graves with nodules (n=57) (dotted lines). EU, euthyroidism;
hypo, hypothyroidism; hyper, hyperthyroidism; RAI, radioactive iodine.
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for 10 years and might be expected to continue for an
average of 15 years [11]. This approach was associated
with continued requirement for oral antithyroid therapy
in about a quarter of patients for 18 months. It should be
noted that none became overtly hyperthyroid.
Importantly, we excluded patients with cardiac compli-
cations in whom hyperthyroidism needed to be corrected
more rapidly.
An absorbed thyroid dose of 60 Gy was chosen for this
study after a previous study at this centre demonstrated a
high rate of treatment failure at 12 months with lower
absorbed doses [9]. Howarth et al. [12] in a study of
patients with Graves’ disease comparing 60 and 90 Gy
absorbed doses to the thyroid reported 46% of patients
were euthyroid on no specific medication with a median
follow-up of 37.5 months. The authors concluded that
60 Gy was a better option than 90 Gy where the aim of
treatment was to achieve euthyroidism and to delay the
onset of hypothyroidism for as long as possible.
The difference between intended and therapeutically
achieved target absorbed doses in Graves’ disease varies
widely in previous publications. The coefficient of variation
of 22.8% in this study compares well with previous reports of
18–28% [13,14] and is considerably lower than others [15].
We noted a significant correlation between pretherapy
thyroid volume (and hence thyroid mass) and treatment
outcome and this may be relevant when comparing our
results with other studies; Thyroid mass (>26 g) has pre-
viously been shown to be an important predictor of inade-
quate response to 131I therapy for patients treated with
60–90Gy [12,13]. The relatively small mean thyroid volume
(18ml) in this study is likely to be an important factor in
determining the successful outcome of our patients.
Reliance on single measurements of 131I uptake at 24 h to
determine activity is potentially inaccurate because of the
variability of the biological half-life of 131I [16,17].
Maximum 131I uptake occurs after 24 h in 54% of patients
with Graves’ disease [18]. This may be important in
interpretation of the results of previous studies compar-
ing individualized and fixed activity approaches [5,19,20].
In our study, 131I uptake was measured over 6 days and
there was good correlation between diagnostic and ther-
apeutic maximum uptake values. A wide variation in 131I
effective half-life was noted in this study although the
Table 4 Odds ratios at 3, 5 and 10 years for achieving a euthyroid state
Thyroid volume (ml) Age at treatment (years) Effective half-life of iodine-131 (days)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
3 years 1.04 (1.01–1.07) 0.005 0.97 (0.95–0.99) 0.030 1.00 (0.81–1.23) 0.994
5 years 1.04 (1.01–1.07) 0.008 0.97 (0.95–0.99) 0.007 1.04 (0.84–1.28) 0.746
10 years 1.03 (1.00–1.06) 0.029 0.97 (0.95–0.99) 0.007 1.04 (0.85–1.29) 0.677
CI, confidence interval; OR, odds ratio.
Fig. 2
Radiation response to 60Gy for the euthyroid group on the basis of age at administration.
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mean of 5.3 days compares well with previous reports
[12,13].
A shorter 131I effective half-life was found to be asso-
ciated with an increased risk of hypothyroidism at 3 years
in keeping with previous reports [21] although we did not
find an association with maximum fractional 131I uptake.
There may be a need to increase the target absorbed dose
in cases where the effective half-life as determined from
the tracer administration is found to be short.
Older patients in our study were more likely to become
euthyroid after a single administration of 131I possibly
indicating less severe hyperthyroidism at the outset.
Pretreatment with propylthiouracil but not carbimazole
may influence treatment outcomes after 131I therapy [22].
However the use of this drug in our patients was limited
to a small number of all ages who developed skin reac-
tions to carbimazole.
The presence of nodules on ultrasonography in Graves’
patients may be an additional confounding factor in the
comparison of outcomes from different studies. Patients
with autonomous thyroid nodules or toxic adenomas were
excluded from our study as with a number of other pre-
viously reported studies [12,20]. Patients with nodular
disease have conventionally been considered to be more
radioresistant in comparison to those with typical Graves’
disease [23] although at least one study has noted that
these patients may have better long-term results after a
single administration of 131I therapy [24]. Our data sug-
gest that patients with Graves’ in a nodular thyroid have a
good response to 131I therapy.
There have been few prospective randomized-controlled
trials comparing individualized dosimetry versus fixed
activity approaches [5,20,25]. In an open randomized
12-month trial comparing three fixed 131I activities with
an individualized absorbed dose equivalent to 70 Gy [20],
50% of patients treated by the individualized dose were
euthyroid, 41% still required antithyroid treatment and
9% were hypothyroid. Results for the fixed activity
approach were similar. No long-term data was presented.
In another randomized trial, 98 patients with Graves’
disease received a fixed activity of 555MBq and were
compared by outcome at 6 months to 107 patients who
were administered a planned absorbed dose of 100 Gy
[25]. A successful outcome, defined as elimination of
hyperthyroidism, occurred in 71% of those receiving
fixed activity versus 58% in the calculated absorbed dose
group. This difference did not quite achieve significance.
Long-term outcomes were not reported. Leslie et al. [5]
randomized 88 patients with Graves’ disease to either (i)
235MBq; (ii) 350MBq; (iii) 2.96MBq/g thyroid (∼60 Gy)
or (iv) 4.44MBq/g thyroid (∼100 Gy). With a mean
follow-up of 63 months, the investigators reported no
significant differences in clinical outcomes. This study
was considerably underpowered and clinically important
differences between groups may have been missed.
Irrespective of whether the objective of 131I therapy is
the elimination of hyperthyroidism or the maintenance of
euthyroidism for as long as possible, the principle of
ensuring that radiation doses as low as reasonably
achievable (ALARA) should be applied [7,26]. This
principle is not always respected in the treatment of
thyroid disease [11]. In our study, a very wide range of
activity (mean: 106MBq; range 17.4–1377MBq) was
associated with a targeted absorbed dose of 60 Gy
reflecting the poor correlation between administered
activity and the absorbed dose. Only five of our patients
required the Royal College of Physicians recommended
fixed activity of 400MBq. Even a fixed activity of
370MBq may result in some two-thirds of patients being
unnecessarily over-irradiated [4,11].
It is acknowledged that a dosimetric approach entails
more visits to hospital with associated costs and the
increased risk of recurrent hyperthyroidism in compar-
ison with a fixed ablative dose. In patients with cardio-
vascular disease this could have serious consequences,
and hence significant cardiac disease is, in our view, a
contraindication to this approach. Furthermore, if
patients are lost to follow-up, there is the potential for
untreated hypothyroidism but this is also the case for
patients receiving fixed doses.
The strengths of this study include: (i) a well-
characterized cohort of patients all treated in one centre
using a standard protocol, in whom cardiac disease was
excluded and in whom the presence of thyroid nodules
was taken into account in the analysis; (ii) achievement of
the targeted absorbed dose of 60 Gy with an acceptable
coefficient of variation; (iii) prolonged follow-up with
results at 10 years and (iv) outcome measurement of
euthyroidism requiring no specific therapy as the pre-
ferred measure of successful treatment. A limitation of
the study is that we did not directly compare outcomes
with patients treated with fixed 131I activities in a
randomized-controlled trial design.
On the basis of our results, a dosimetric approach would
have resulted in nearly two-thirds of patients receiving an
average of three to five times less radioiodine compared
with standard fixed radiation activities of 370–550MBq.
Further research is needed to identify the optimal absor-
bed dose for different patient cohorts and investigate
which patients would benefit most from this approach.
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